Woodside Manor Nursing Home Inc | |
2425 Clinton Avenue South, Rochester, New York 14618 | |
(585) 461-0370 | |
Name | Woodside Manor Nursing Home Inc |
---|---|
Location | 2425 Clinton Avenue South, Rochester, New York |
Certified By | Medicare and Medicaid |
No. of Certified Beds | 44 |
Occupancy Rate | 75.23% |
Medicare ID (CCN) | 335366 |
Legal Business Name | Woodside Manor Nursing Home Inc |
Ownership Type | For Profit - Individual |
NPI Number | 1528063658 |
Organization Name | WOODSIDE MANOR NURSING HOME, INC. |
Address | 2425 Clinton Ave S, Rochester, NY 14618 |
Phone Number | 585-461-0370 |
News Archive
A common food additive, recently banned in France but allowed in the U.S. and many other countries, was found to significantly alter gut microbiota in mice, causing inflammation in the colon and changes in protein expression in the liver, according to research led by a University of Massachusetts Amherst food scientist.
Simbionix USA Corporation, the world's leading provider of medical education and simulation training products for medical professionals and the healthcare industry, is pleased to announce its new training simulator for pelvic floor repair, to be exhibited for the first time at the ACOG 59th Annual Clinical Meeting in Washington, DC, April 30- May 4, 2011.
Experimenting with mice, Johns Hopkins researchers report they have successfully used positron emission tomography scans to calculate in real time how much of an immunotherapy drug reaches a tumor and what parts of a cancer remain unaffected.
Zalicus Inc. a biopharmaceutical company that discovers and develops novel treatments for patients suffering from pain and immuno-inflammatory diseases today announced the initiation of the SYNERGY trial, a Phase 2b clinical trial evaluating Synavive, a low-dose glucocorticoid with the potential for amplified immuno-inflammatory benefits, in patients with rheumatoid arthritis (RA).
› Verified 5 days ago
Ratings from Surveys (Inspections): | |
Ratings from Quality Measures: | |
Ratings from Staffing Data: | |
Overall Rating: |
---|
News Archive
A common food additive, recently banned in France but allowed in the U.S. and many other countries, was found to significantly alter gut microbiota in mice, causing inflammation in the colon and changes in protein expression in the liver, according to research led by a University of Massachusetts Amherst food scientist.
Simbionix USA Corporation, the world's leading provider of medical education and simulation training products for medical professionals and the healthcare industry, is pleased to announce its new training simulator for pelvic floor repair, to be exhibited for the first time at the ACOG 59th Annual Clinical Meeting in Washington, DC, April 30- May 4, 2011.
Experimenting with mice, Johns Hopkins researchers report they have successfully used positron emission tomography scans to calculate in real time how much of an immunotherapy drug reaches a tumor and what parts of a cancer remain unaffected.
Zalicus Inc. a biopharmaceutical company that discovers and develops novel treatments for patients suffering from pain and immuno-inflammatory diseases today announced the initiation of the SYNERGY trial, a Phase 2b clinical trial evaluating Synavive, a low-dose glucocorticoid with the potential for amplified immuno-inflammatory benefits, in patients with rheumatoid arthritis (RA).
› Verified 5 days ago
Number of Facility Reported Incidents | 0 |
Number of Substantiated Complaints | 0 |
Number of Fines | 0 |
Total Amount of Fines in Dollars | $0 |
Number of Payment Denials | 0 |
Total Number of Penalties | 0 |
Experience Measure | Provider | National Avg. |
---|---|---|
Percentage of long-stay residents whose need for help with daily activities has increased | 6.11 | 14.46 |
Percentage of long-stay residents who lose too much weight | 6.87 | 5.51 |
Percentage of low risk long-stay residents who lose control of their bowels or bladder | 86.89 | 48.41 |
Percentage of long-stay residents with a catheter inserted and left in their bladder | 0.5 | 1.79 |
Percentage of long-stay residents with a urinary tract infection | 1.53 | 2.65 |
Percentage of long-stay residents who have depressive symptoms | 2.4 | 5.05 |
Percentage of long-stay residents who were physically restrained | 0 | 0.23 |
Percentage of long-stay residents experiencing one or more falls with major injury | 5.3 | 3.36 |
Percentage of long-stay residents assessed and appropriately given the pneumococcal vaccine | 93.18 | 93.87 |
Percentage of long-stay residents who received an antipsychotic medication | 8.33 | 14.2 |
Percentage of short-stay residents assessed and appropriately given the pneumococcal vaccine | 70.24 | 83.88 |
Percentage of short-stay residents who newly received an antipsychotic medication | 0 | 1.79 |
Percentage of long-stay residents whose ability to move independently worsened | 19.06 | 17.09 |
Percentage of long-stay residents who received an antianxiety or hypnotic medication | 0 | 19.7 |
Percentage of high risk long-stay residents with pressure ulcers | 5.93 | 7.32 |
Percentage of long-stay residents assessed and appropriately given the seasonal influenza vaccine | 97.93 | 95.98 |
Percentage of short-stay residents who made improvements in function | 55.83 | 67.99 |
Percentage of short-stay residents who were assessed and appropriately given the seasonal influenza vaccine | 88.89 | 82.93 |
News Archive
A common food additive, recently banned in France but allowed in the U.S. and many other countries, was found to significantly alter gut microbiota in mice, causing inflammation in the colon and changes in protein expression in the liver, according to research led by a University of Massachusetts Amherst food scientist.
Simbionix USA Corporation, the world's leading provider of medical education and simulation training products for medical professionals and the healthcare industry, is pleased to announce its new training simulator for pelvic floor repair, to be exhibited for the first time at the ACOG 59th Annual Clinical Meeting in Washington, DC, April 30- May 4, 2011.
Experimenting with mice, Johns Hopkins researchers report they have successfully used positron emission tomography scans to calculate in real time how much of an immunotherapy drug reaches a tumor and what parts of a cancer remain unaffected.
Zalicus Inc. a biopharmaceutical company that discovers and develops novel treatments for patients suffering from pain and immuno-inflammatory diseases today announced the initiation of the SYNERGY trial, a Phase 2b clinical trial evaluating Synavive, a low-dose glucocorticoid with the potential for amplified immuno-inflammatory benefits, in patients with rheumatoid arthritis (RA).
› Verified 5 days ago
St Johns Health Care Corporation Location: 150 Highland Avenue, Rochester, New York 14620 Phone: (585) 271-5413 | |
Jewish Home Of Rochester Location: 2021 Winton Road South, Rochester, New York 14618 Phone: (585) 427-7760 | |
Monroe Community Hospital Location: 435 East Henrietta Road, Rochester, New York 14620 Phone: (585) 760-6500 | |
Church Home Of The Protestant Episcopal Church Location: 505 Mt Hope Avenue, Rochester, New York 14620 Phone: (585) 546-8400 |